drugset

drugset / Trial / NCT02101593

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

NCT02101593 ↗

Phase 1 Completed 8 enrolled Polaris Group

NaSingle-groupOpen-labelTreatment

Summary

Assessment of safety and tolerability of ADI-PEG 20 in combination with sorafenib in advanced Hepatocellular Carcinoma (HCC).

Timeline

Start: 2014-11
Primary completion: 2016-02
Completion: 2016-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pegargiminase	Protein / enzyme biologic	—	—

Indications